OGN Earnings Date: Nov 9, 2026 (Estimated) — Organon & Co.
NYSE · Healthcare · Drug Manufacturers - General
Updated
When is OGN's next earnings date?
Organon & Co. (OGN) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.88 on revenue of $1.58B.
How did OGN do in its last earnings report?
In its most recent report on Oct 30, 2026, Organon & Co. posted EPS of $0.94 versus the $0.88 estimate, a beat of 6.8%. Revenue was $1.57B against a $1.58B estimate.
How much does OGN stock move after earnings?
OGN beat EPS estimates in 5 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 7.4% (up or down) in the day after earnings.
About Organon & Co.
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
🤖 AI Earnings Analysis
Organon’s $0.94 EPS beat estimates by $0.06, but revenue merely met $1.6B and reported growth figures are sharply negative. This is a mixed, fragile result for the drugmaker, not evidence of a turnaround.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | 0.88 | 0.94 | +6.82% | $1.57B | ✅ Beat | — | — | — | |
| 2026-07-31 | Q2 2026 | 1.03 | 0.85 | -17.48% | $1.56B | ❌ Miss | +0.00% | +0.00% | +1.70% |
| 2026-04-30 | Q1 2026 | 0.84 | 0.71 | -15.48% | $1.46B | ❌ Miss | -0.68% | +0.53% | +0.15% |
| 2026-02-12 | Q4 2025 | 0.72 | 0.63 | -12.50% | $1.51B | ❌ Miss | -8.19% | -2.21% | -17.22% |
| 2025-11-10 | Q3 2025 | 0.92 | 1.01 | +9.78% | $1.60B | ✅ Beat | +13.72% | +11.06% | +2.78% |
| 2025-08-05 | Q2 2025 | 0.92 | 1.00 | +8.70% | $1.59B | ✅ Beat | -13.13% | -6.82% | +1.88% |
| 2025-02-13 | Q4 2024 | 0.87 | 0.90 | +3.45% | $1.59B | ✅ Beat | +11.09% | +6.74% | +6.11% |
| 2024-10-31 | Q3 2024 | 0.90 | 1.03 | +14.44% | $1.58B | ✅ Beat | +4.74% | -11.89% | -9.89% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q3 FY26 · $2.74B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Non-US | 42.5% | $1.16B | — | — | — | — | — |
| Europe And Canada | 15.2% | $417.0M | 0.0% | $376.0M | $419.0M | $417.0M | $406.0M |
| UNITED STATES | 15.0% | $411.0M | +1.2% | $412.0M | $414.0M | $406.0M | $372.0M |
| Latin America, Middle East, Russia And Africa | 9.8% | $269.0M | -5.9% | $240.0M | $285.0M | $286.0M | $261.0M |
| Asia Pacific and Japan | 8.5% | $234.0M | -6.8% | $251.0M | $250.0M | $251.0M | $248.0M |
| CHINA | 8.3% | $226.0M | +3.2% | $204.0M | $204.0M | $219.0M | $202.0M |
| Other Countries | 0.6% | $17.0M | -26.1% | $30.0M | $22.0M | $23.0M | $18.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.